PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25053825-2 2014 Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34(+) human AML blast progenitor cells (BPC) expressing FLT3-ITD. ponatinib 92-101 fms related receptor tyrosine kinase 3 Homo sapiens 55-59 33194747-6 2020 Patients 2 and 3 showed some response to combined FLT3-inhibitor and BCR-ABL targeted therapy (gilteritinib and ponatinib). ponatinib 112-121 fms related receptor tyrosine kinase 3 Homo sapiens 50-54 32095692-6 2020 A nicotinamide analogue of ponatinib, HSN748, retains activity against FLT3, ABL1, RET, and PDGFRalpha/beta but loses activity against c-Src and P38alpha. ponatinib 27-36 fms related receptor tyrosine kinase 3 Homo sapiens 71-75 25053825-2 2014 Here, we demonstrate that cotreatment with JQ1 and the FLT3 tyrosine kinase inhibitor (TKI) ponatinib or AC220 synergistically induce apoptosis of cultured and primary CD34(+) human AML blast progenitor cells (BPC) expressing FLT3-ITD. ponatinib 92-101 fms related receptor tyrosine kinase 3 Homo sapiens 226-230 23430109-5 2013 Substitution of the FLT3 "gatekeeper" phenylalanine with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance. ponatinib 102-111 fms related receptor tyrosine kinase 3 Homo sapiens 20-24 23430109-0 2013 Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. ponatinib 12-21 fms related receptor tyrosine kinase 3 Homo sapiens 91-95 23430109-3 2013 Ponatinib has demonstrated early clinical efficacy in chemotherapy-resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in FLT3. ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 167-171 23430109-4 2013 We assessed the in vitro activity of ponatinib against clinically relevant FLT3-ITD mutant isoforms that confer resistance to AC220 or sorafenib. ponatinib 37-46 fms related receptor tyrosine kinase 3 Homo sapiens 75-79 22409268-0 2012 Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 37-41 22778153-0 2012 The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. ponatinib 37-46 fms related receptor tyrosine kinase 3 Homo sapiens 22-26 22778153-1 2012 Ponatinib is a novel tyrosine kinase inhibitor with potent activity against BCR-ABL with mutations, including T315I, and also against fms-like tyrosine kinase 3. ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 134-160 22409268-5 2012 Ponatinib effectively induced apoptosis not only in the parental FLT3-ITD cell line but also in all stably transfected subclones harbouring additional FLT3-TKD point mutations (N676D, F691I or G697R). ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 65-69 22409268-5 2012 Ponatinib effectively induced apoptosis not only in the parental FLT3-ITD cell line but also in all stably transfected subclones harbouring additional FLT3-TKD point mutations (N676D, F691I or G697R). ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 151-155 22409268-6 2012 These observations correlated with a strong inhibition of FLT3-ITD and its downstream targets STAT5, AKT and ERK1/2 upon ponatinib incubation, as determined by Western blotting. ponatinib 121-130 fms related receptor tyrosine kinase 3 Homo sapiens 58-62 22409268-7 2012 We conclude that ponatinib represents a promising FLT3-TKI that should be further investigated in clinical trials. ponatinib 17-26 fms related receptor tyrosine kinase 3 Homo sapiens 50-54 22409268-8 2012 The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations. ponatinib 51-60 fms related receptor tyrosine kinase 3 Homo sapiens 24-28 22409268-8 2012 The targeted therapy of FLT3-ITD-positive AML with ponatinib might be associated with a lower frequency of secondary resistance caused by acquired FLT3-TKD mutations. ponatinib 51-60 fms related receptor tyrosine kinase 3 Homo sapiens 147-151 21482694-0 2011 Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. ponatinib 19-28 fms related receptor tyrosine kinase 3 Homo sapiens 52-56 21482694-2 2011 Ponatinib also has in vitro inhibitory activity against a discrete set of kinases implicated in the pathogenesis of other hematologic malignancies, including FLT3, KIT, fibroblast growth factor receptor 1 (FGFR1), and platelet derived growth factor receptor alpha (PDGFRalpha). ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 158-162 21482694-4 2011 The activity of ponatinib against the FLT3-ITD mutant, found in up to 30% of acute myeloid leukemia (AML) patients, was particularly notable. ponatinib 16-25 fms related receptor tyrosine kinase 3 Homo sapiens 38-42 21482694-5 2011 In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(-/-)) AML cells, ponatinib inhibited FLT3 signaling and induced apoptosis at concentrations of less than 10 nmol/L. ponatinib 68-77 fms related receptor tyrosine kinase 3 Homo sapiens 11-15 21482694-7 2011 Ponatinib inhibited viability of primary leukemic blasts from a FLT3-ITD positive AML patient (IC50 4 nmol/L) but not those isolated from 3 patients with AML expressing native FLT3. ponatinib 0-9 fms related receptor tyrosine kinase 3 Homo sapiens 64-68 21482694-8 2011 Overall, these results support the investigation of ponatinib in patients with FLT3-ITD-driven AML and other hematologic malignancies driven by KIT, FGFR1, or PDGFRalpha. ponatinib 52-61 fms related receptor tyrosine kinase 3 Homo sapiens 79-83